MS
KNTE

Maven Securities’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Maven Securities’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,952
Closed -$237K – 1332
2020
Q4 		$237K Buy
+5,952
New +$239K 0.02% 475

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's KNTE Position: Q1 2021 in Review

Maven Securities sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2021, closing a stake of 5,952 shares — an estimated $237K sold.

Maven Securities first reported a position in KNTE in Q4 2020 and held it in 1 quarter. The position peaked at $237K in Q4 2020. 62 funds tracked by Wall St. Rank hold KNTE as of Q1 2021.

  • Maven Securities reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 5,952 Kinnate Biopharma Inc. Common Stock shares in Q1 2021, an estimated $237K.
  • Maven Securities first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Maven Securities's Kinnate Biopharma Inc. Common Stock position peaked at $237K in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.